Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.58 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.58 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.58 |
| ▸ | PAK4 | O96013 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 4/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983274 | 0.91 | NTRK1 (0.65) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1984517 | 0.91 | CDK2 (0.60) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1982354 | 0.91 | NTRK1 (0.60) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1986540 | 0.90 | CDK2 (0.59) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL3484541 | 0.90 | NTRK1 (0.58) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1985408 | 0.90 | NTRK1 (0.62) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1984674 | 0.90 | CDK2 (0.58) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1984379 | 0.90 | CDK2 (0.58) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1985632 | 0.90 | CDK2 (0.60) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL1984361 | 0.89 | NTRK1 (0.61) | CDK2CCNA2CCNA1NTRK1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227472-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-07-24 | — | — | US | claimed |
| EP-2089394-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2011-06-29 | — | — | EP | claimed |
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-14 | — | — | US | claimed |
| EP-2089394-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-08-19 | — | — | EP | claimed |
| WO-2008043745-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-04-17 | — | — | WO | claimed |
| US-8623876-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-07 | — | — | US | disclosed |
| US-20120277248-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-01 | — | — | US | disclosed |
| US-8227472-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-07-24 | — | — | US | disclosed |
| EP-2089394-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-14 | — | — | US | disclosed |
| EP-2089394-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008043745-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K3, MAP3K15 | CDK2 148/4885CCNA2 1698/4885CCNA1 1208/4885 |
| US-20120277248-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K3, MAP3K15 | CDK2 148/4885CCNA2 1698/4885CCNA1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.